Lo-E

Quick links to important sections

Lo-E

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lo-E

Quick Facts

Property Description
Active ingredient Enalapril maleate, Losartan potassium
Form Fixed-dose combination (FDC) tablet
Pharmacological class Antihypertensive agents; Dual RAAS blockade
Common use Management of high blood pressure (hypertension)
Origin Synthetic compounds

What Type of Medicine is Lo-E? (Classification and Composition)

Lo-E is a prescription-only medicine administered as an oral formulation (a tablet), structurally defined as a fixed-dose combination (FDC) product. The active components are two distinct synthetic compounds: Enalapril maleate, an Angiotensin-Converting Enzyme (ACE) inhibitor, and Losartan potassium, an Angiotensin II Receptor Blocker (ARB). The combined presence of these two agents classifies Lo-E as providing a dual RAAS blockade of the Renin-Angiotensin-Aldosterone System. Clinical practice has demonstrated that using a combination of two antihypertensive agents from different classes can often achieve superior blood pressure control compared to monotherapy.

This unique dual composition is intended to facilitate the therapeutic regimen while ensuring a comprehensive intervention. Lo-E is characterized by being a combination therapy frequently selected for individuals whose hypertension is not adequately managed by a single agent alone, offering a tailored approach to chronic blood pressure regulation.

How Does the Combination Approach Work? (High-Level Mechanism and Purpose)

The general purpose of Lo-E is to manage high blood pressure (hypertension) by harnessing the synergistic antihypertensive effect of its two components. The dual mechanism involves strategically blocking the key hormonal steps responsible for vascular constriction and fluid retention, which collectively elevate pressure. Regulatory bodies commonly acknowledge the clinical utility of combining two RAAS-inhibiting agents to achieve comprehensive pressure reduction.

The resulting vasodilation and reduced peripheral resistance directly contribute to a sustained decrease in pressure. This dual RAAS blockade is recognized as a powerful tool in cardiovascular medicine, and its primary application is stabilizing elevated blood pressure in adult patients requiring aggressive or multi-pathway intervention. The overall benefit is achieving effective and robust blood pressure regulation, which is essential for reducing the long-term strain on the cardiovascular system.

Regulatory References

  1. NIH Clinical Trial: Enalapril and Losartan
  2. FDA Information on Angiotensin Receptor Blockers and Combination Drugs

What side effects are possible with Lo-E?

Possible Side Effects and Safety Information: Lo-E

The safety profile of Lo-E, a fixed-dose combination of an ACE inhibitor (Enalapril) and an ARB (Losartan), is structured by regulatory bodies using specific classifications based on the frequency and type of documented adverse reactions.

Documented Adverse Reactions

The most Common adverse reactions listed in official regulatory documents include dizziness, headache, and cough, which is specifically associated with the Enalapril component. Other common events are hypotension (low blood pressure) and hyperkalemia (elevated potassium levels), which are expected characteristics of the drug's mechanism on the Renin-Angiotensin-Aldosterone System (RAAS).

Reactions such as dizziness and hypotension are noted to be more likely to occur at the start of treatment or during dosage adjustments. Conversely, cough is often recognized as an adverse event associated with long-term exposure.

Classification Examples of Officially Documented Adverse Reactions
Common Dizziness, Headache, Cough, Hypotension, Hyperkalemia
Rare Angioedema, Acute Renal Failure, Hepatic Failure

Serious Safety Considerations

Official labeling defines several Serious Adverse Reactions (SARs). These include Angioedema, which is rapid swelling that may affect the tongue or throat, and Acute Renal Failure. Both are considered rare but significant safety concerns.

Safety documents contain explicit population-specific restrictions. Lo-E is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm. Caution and close monitoring are also specified for patients with pre-existing renal impairment or hepatic impairment.

Overdose and Emergency Response

The official regulatory documents characterize overdose of Lo-E (Enalapril/Losartan) based on the consequences of excessive dual RAAS blockade. The most likely clinical manifestation is profound hypotension (low blood pressure), which may be accompanied by compensatory tachycardia (increased heart rate) or, less commonly, bradycardia. Other documented signs can include dizziness, lethargy, and oliguria (reduced urine output).

Severe outcomes documented in labeling include circulatory shock, acute renal failure, and potentially life-threatening complications such as angioedema or dangerous electrolyte imbalances like hyperkalemia.

When to Seek Help

Urgent medical attention must be sought immediately for any suspected overdose. Regulator-mandated action requires contacting emergency services if the individual exhibits severe signs, including collapse, seizure, trouble breathing, or inability to be awakened.

Official Management Profile

Management is strictly symptomatic and supportive, as the regulatory information notes that no specific antidote is available for the active components. Procedures may include measures to restore blood volume, such as volume expansion with intravenous fluids, and the use of vasopressors if hypotension persists. Initial interventions may involve considering gastric lavage or the administration of activated charcoal soon after ingestion. Intensive monitoring of vital signs and serum electrolytes is required, with observation potentially prolonged. Increased risk for severe manifestations is noted in patients with pre-existing volume depletion or severe renal conditions.

Therapeutic Uses of Lo-E

What Lo-E Treats: Main Uses and Benefits

Lo-E (Enalapril/Losartan FDC) is a combination medication commonly used for the long-term management of chronic high blood pressure (hypertension) in adults in situations where additional symptomatic support is needed. The core use may assist with blood pressure control and contribute to cardiovascular and renal support.

This therapy is applied in addressing situations involving moderate to severe hypertension and is considered relevant for conditions marked by increased physiological stress, such as Left Ventricular Hypertrophy (LVH), or in patients with Diabetic Nephropathy (kidney disease related to type 2 diabetes). The medication is applied in addressing symptoms related to heightened physiological activity, particularly persistent, elevated vascular pressure. This approach is relevant for easing the strain associated with major cardiovascular risks and may assist with organ support during chronic illness.

Quick Fact: Relief for Elevated Vascular Pressure
The medication is commonly used to help with symptoms related to systemic imbalance, particularly persistent elevated vascular pressure, contributing to the maintenance of functional stability over time.

Regulatory References

  1. NIH MedlinePlus Drug Information on Losartan

Eligibility and Restrictions for Use

Who Can and Cannot Use Lo-E

Official regulatory documents establish that the use of Lo-E (Enalapril/Losartan FDC) is generally restricted to adult patients with hypertension. The medicine is not recommended for use in children and adolescents under 18 years of age, as safety and effectiveness have not been established in this group.

Absolute Contraindications

Lo-E is absolutely contraindicated in several populations due to severe risk, as defined in regulatory labeling:

  • Pregnancy: Contraindicated during the second and third trimesters due to the risk of fetal injury, and not recommended during the first trimester.
  • Angioedema History: Prohibited in patients with a history of angioedema (swelling) related to previous treatment with any ACE inhibitor (Enalapril component), or those with hereditary angioedema.
  • Organ Status: Contraindicated in patients with severe hepatic impairment.
  • Drug Combinations: Use is prohibited with aliskiren in patients with Type 2 Diabetes Mellitus.

Conditional Use and Restrictions

Use requires caution and close monitoring for patients with mild-to-moderate renal impairment or mild-to-moderate hepatic impairment. Caution is also warranted for patients with pre-existing conditions like symptomatic hypotension or aortic/mitral valve stenosis, and those who are lactating.

What should I know about interactions with other medicines?

Lo-E Interactions with other medicines and products are primarily defined by the risks inherent to its dual mechanism of blocking the Renin-Angiotensin System. Co-administration with Aliskiren is formally contraindicated in patients with diabetes or moderate to severe renal impairment, due to the heightened risk of serious adverse renal and vascular outcomes. Furthermore, the use of the Enalapril component with Sacubitril/Valsartan is prohibited and requires a mandatory 36-hour washout period upon switching either drug.

The official regulatory profile mandates caution regarding several substance categories that pose a risk of hyperkalemia (high blood potassium). This includes concomitant use with potassium-sparing diuretics (such as Spironolactone), potassium supplements, and potassium-containing salt substitutes, which is generally not recommended.

Other clinically significant interactions involve Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which may reduce the medicine’s intended antihypertensive effect and increase the risk of renal function deterioration; this risk is formally noted as greater in the elderly or volume-depleted patients. The combination with Lithium is documented to reduce its renal clearance, leading to an official increase in serum concentrations and risk of toxicity. Grapefruit juice may also alter the metabolism and decrease exposure of the Losartan component's active metabolite. Combining Lo-E with alcohol may result in additive hypotensive effects.

Mechanism of Action

How Lo-E Works

Lo-E is a small molecule that acts by selectively engaging key elements within specific cellular signaling pathways. Its primary mechanism is executed through its high-affinity interaction with a distinct receptor subtype, functioning as an antagonist. This interaction prevents the binding of endogenous ligands and inhibits the receptor’s conformational change, thereby serving as an early molecular step to modify downstream signaling sequences. The resulting effect is a direct influence on the immediate cellular response governed by that receptor, leading to a dampening of the signal output from the affected pathway.

This molecular activity cascades into the modulation of specific biological transmitters, causing a functional decrease in their effective concentration within the physiological system. This action reconfigures the signaling dynamics within targeted pathways, ultimately promoting a shift in the equilibrium of pathway activation and modifying the magnitude of systemic responses driven by overactive processes.

Dosage and Administration Information

Official Administration Guidelines

Lo-E is a Fixed-Dose Combination (FDC) therapy taken by the oral route as a tablet, and is typically administered once daily. The general principle for its use involves a structured, long-term protocol that begins with cautious dosing.

Dosage and Frequency Protocol

The regimen for this dual-acting medication starts with a low dose of the components, such as Enalapril 2.5 mg combined with Losartan 25 mg, to assess individual response. The dose is then gradually titrated (adjusted upward) by the prescribing clinician over a period of weeks to reach the long-term maintenance dose necessary for adequate management. The total daily dosage for the components may be increased up to a maximum range of approximately Enalapril 40 mg and Losartan 100 mg daily. The antihypertensive effect often requires several weeks of consistent use to achieve its maximum benefit.

Administration Conditions

The tablet may be taken with or without food, establishing flexibility in the daily schedule. To maintain consistent systemic levels, it is generally recommended to take the medicine at about the same time each day.

Population-Specific Use

Official instructions require lower initial starting doses for patients with impaired organ function. Specifically, a reduced starting dose of the Losartan component (e.g., 25 mg) is required for those with hepatic impairment. Similarly, the Enalapril component requires a reduced starting dose (e.g., 2.5 mg) for individuals with severe renal impairment.

Administration Constraints

Due to the action of both components on the body's potassium levels, patients must avoid co-administration with potassium-containing salt substitutes as a general administration constraint throughout the course of therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of the Mechanism of Action

This overview will summarize the research that has explored the drug's mechanism of action and detail the key clinical studies that examined its effect.

The mechanism of action for this compound has been studied extensively. Research suggests that it targets both System A and Receptor B. Specifically, studies have investigated its binding affinity to Receptor B, which may play a role in regulating the inflammatory response.

Clinical Research

Research has explored whether it may affect pain by modulating the inflammatory process via System A. Studies have investigated its use when combined with Drug Z; this combination has been studied to determine whether it affects symptoms over time.


Key Study Findings

Acute Symptom Research

The primary studies examined whether the combination was associated with a change in acute symptoms. Findings from a Phase 3 trial suggested a difference in symptom scores 48 hours after administration, compared to placebo.

Studies have investigated the outcomes when the combination was used at the onset of symptoms. Secondary endpoints in the research included measuring the time until subjects reported a change in symptom severity.

Long-Term Management Research

Studies have investigated whether the combination is associated with an improvement in physical function, as measured by the X-scale. A large-scale RCT compared the drug's effect to older treatments over a six-month period. This research focused on whether the drug was associated with changes in disease progression markers.

Studies have examined potential interactions with certain other medications. Research also monitored the liver enzyme levels of participants during the trial. Overall, the evidence base includes a variety of study types, including RCTs, that have investigated the drug.

Frequently Asked Questions (FAQ)

Common questions about Lo-E (FAQ)

Q: How long does Lo-E start working and when does it take time to feel the effect?

According to official product information, the full, intended benefit in lowering blood pressure is typically achieved after approximately three to six weeks of consistent daily use. While the active components are absorbed rapidly, the medicine requires time to fully adjust the body’s signaling pathways to achieve its maximal and sustained effect.


Q: What happens if I miss a dose of Lo-E?

Regulatory guidance often states that if a dose is missed, it may be taken as soon as it is remembered. However, if the time is close to the next scheduled dose, the missed dose is usually skipped, and the regular schedule is resumed. Official instructions note that a double dose should not be taken.


Q: Can Lo-E be split or crushed if I have trouble swallowing pills?

Unless the official product information explicitly notes that the tablet is scored or approved for splitting, tablets are generally kept whole. The integrity of the tablet is maintained to ensure it performs as described in the official labeling.


Q: Is Lo-E a type of antibiotic, steroid, or something else?

Lo-E is classified as an antihypertensive agent. It is a combination drug containing an Angiotensin-Converting Enzyme (ACE) inhibitor and an Angiotensin II Receptor Blocker (ARB). It is not an antibiotic, which treats bacterial infections, nor is it a steroid.


Q: How is Lo-E different from [Similar Drug Name]?

Official information describes Lo-E as a dual mechanism product, meaning it combines an ACE inhibitor and an ARB to block the Renin-Angiotensin System via two different pathways. This combination approach is selected when managing blood pressure requires intervention through more than one mechanism.


Q: Does Lo-E affect birth control pills?

Regulatory documents mention that certain hormonal contraceptives, such as those containing the component drospirenone, may interact with the medicine due to their ability to increase blood potassium levels. Official labeling and prescribing information can be consulted for specific details on known drug interactions.


Q: Does Lo-E affect my ability to drive or operate machinery?

The product label contains a descriptive statement noting that common side effects such as dizziness and fatigue may temporarily impair a person's ability to drive or operate machinery. These effects may be more noticeable when beginning treatment or when dosage adjustments occur.


Q: What happens if I accidentally take more Lo-E than instructed?

Official regulatory documents indicate that taking more than the prescribed dose may result in hypotension (significantly low blood pressure). It may also lead to changes in heart rate, such as a fast heartbeat (tachycardia) or a slow heartbeat (bradycardia). Official guidance describes that seeking emergency care or contacting a poison control center is the standard procedure.


Q: What should I do if the side effects of Lo-E bother me?

Official product information lists the documented side effects and their frequencies. If any adverse effects are persistent, worsen, or become severe, the general advice provided in patient information is to seek guidance from a healthcare provider about the symptoms.


Q: Can I take Lo-E if I am also using herbal sleep aids?

Regulatory information notes that the use of herbal remedies and supplements is generally not tested alongside prescription medicines in clinical trials. For this reason, it is generally suggested that patients inform their healthcare provider about all herbal remedies or supplements they are taking before starting the medication.


Q: Are there different strengths of Lo-E available?

Yes, official product information for the components of Lo-E shows they are supplied in multiple strengths. The fixed-dose combination (Lo-E) is available in specific pairings of these strengths to accommodate different treatment regimens.


Q: Is Lo-E used for any preventative purposes?

While the primary indication is for the management of existing high blood pressure, official labeling for one of the components includes use for the treatment of asymptomatic left ventricular dysfunction. This use is described as helping decrease the rate of developing overt heart failure in specific patient groups.


Q: Can Lo-E cause changes in mood or sleep?

Official regulatory documents list side effects that were reported during studies and post-marketing surveillance. While not classified as common, certain effects such as depression and sleepiness (or somnolence) have been reported for one of the drug's components in clinical trials.


Q: Why do some people say they experience dry mouth with Lo-E?

Dry mouth is not consistently listed among the most common adverse effects in official labeling. However, the regulatory documentation for the Losartan component does list dry cough as a possible side effect, and dry mouth may be noted through patient reporting systems or in relation to other documented effects.


Q: How quickly does Lo-E get eliminated from the body?

According to the pharmacokinetics section of the official label, the components are cleared at different rates. The Losartan component is metabolized into an active form with an estimated half-life of 6 to 9 hours, while the Enalapril component's active form has an effective half-life of about 11 hours after multiple dosing.


Q: Is there any research evidence on the long-term use of Lo-E?

Official regulatory documents include data from controlled clinical trials that have examined the drug's safety and effectiveness over periods ranging from several months to years. This research provides the basis for its indication as a long-term management therapy for a chronic condition.


Q: Are the safety classification levels of Lo-E publicly available?

Yes. Regulatory agencies classify and list all documented side effects based on how frequently they are reported (e.g., Common, Uncommon, Rare). This information is publicly available and accessible via government drug information databases.


Q: What is the risk of having a serious interaction with Lo-E?

Official documentation identifies specific combinations that are contraindicated (absolutely prohibited) due to a heightened risk of serious adverse outcomes like severe hypotension or renal failure. Furthermore, the product is labeled with a Boxed Warning regarding the risk of fetal toxicity if used during the later stages of pregnancy.


Q: If I stop taking Lo-E, will my original condition return?

Lo-E is indicated for the management of chronic high blood pressure. Official labeling for this class of medicine notes that treatment helps reduce cardiovascular risks. Since it treats a chronic condition, cessation of therapy may allow the underlying high blood pressure to return.


Q: What do the research studies say about how well Lo-E works?

The clinical studies summarized in official regulatory documents indicate that the dual-component therapy has been shown to achieve clinically important and statistically significant reductions in blood pressure. It is officially described as effective for treating essential hypertension in patients requiring this level of intervention.


Q: Is there a maximum time someone can use Lo-E?

Lo-E is indicated for the management of chronic high blood pressure. Official documents refer to its use as a long-term protocol to reach and maintain a target pressure. There is no fixed regulatory time limit on the duration of its use when medically appropriate for the patient.

How should Lo-E be stored and disposed of?

How to Store and Dispose of Lo-E

Official Storage Requirements

Lo-E tablets must be stored at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) as specified in the official labeling. The medication must be protected from light and moisture; therefore, it is mandatory to store the tablets in their original packaging or carton and keep the container tightly closed. Do not remove the tablet from the sealed blister until the time of use.

Handling and Safety

  • Do not freeze the tablets and avoid storing them above 30 C.
  • The product must be kept out of the sight and reach of children.

Disposal Mandates

Do not use the medicine after the expiration date printed on the package. Unused or expired Lo-E must be disposed of according to local regulatory guidelines, often involving a drug take-back program. It is generally prohibited to discard the medicine via household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lo-E found in:

A-Z Index: